Molecular Pathology of Rickettsial Lung Infections

  • J. Stephen Dumler
Part of the Molecular Pathology Library book series (MPLB, volume 1)


Rickettsial infections of humans comprise a diverse group of infections caused by pathogens that are obligate intracellular bacteria with a genetic relationship, including the genera Rickettsia, Orientia, Ehrlichia, and Anaplasma. The host cells of these pathogens largely belie the systemic clinical manifestations, because Rickettsia and Orientia infect endothelial cells, and Ehrlichia and Anaplasma infect circulating leukocytes (monocytes and neutrophils, respectively). Thus, the predominant manifestations (fever, headache, myalgia, with or without rash) do not usually focus attention on the respiratory system; however, the underlying pathogenesis of these infections involves degrees of vascular compromise either by direct injury and inflammation or by the action of vasoactive proinflammatory molecules such as cytokines, chemokines, and prostaglandins. Given that the lung possesses the largest vascular bed in the human body, it is not surprising that pulmonary involvement is periodically identified and, when severely affected, is considered a potentially life-threatening complication.1,2


Mononuclear Phagocyte Diffuse Alveolar Damage Spotted Fever Rickettsial Infection Hematoxylin Counterstain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Walker DH, Valbuena GA, Olano JP. Pathogenic mechanisms of diseases caused by Rickettsia. Ann NY Acad Sci 2003;990:1–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Dumler JS. Anaplasma and ehrlichia infection. Ann NY Acad Sci 2005;1063:361–373.CrossRefPubMedGoogle Scholar
  3. 3.
    Walker DH, Crawford CG, Cain BG. Rickettsial infection of the pulmonary microcirculation: the basis for interstitial pneumonitis in Rocky Mountain spotted fever. Hum Pathol 1980;11:263–272.CrossRefPubMedGoogle Scholar
  4. 4.
    Walker DH, Mattern WD. Rickettsial vasculitis. Am Heart J 1980;100:896–906.CrossRefPubMedGoogle Scholar
  5. 5.
    Walker DH, Yu XJ. Progress in rickettsial genome analysis from pioneering of Rickettsia prowazekii to the recent Rickettsia typhi. Ann NY Acad Sci 2005;1063:13–25.CrossRefPubMedGoogle Scholar
  6. 6.
    Walker DH, Dumler JS. Human monocytic and granulocytic ehrlichioses. Discovery and diagnosis of emerging tickborne infections and the critical role of the pathologist. Arch Pathol Lab Med 1997;121:785–791.PubMedGoogle Scholar
  7. 7.
    Sporn LA, Marder VJ. Interleukin-1 alpha production during Rickettsia rickettsii infection of cultured endothelial cells: potential role in autocrine cell stimulation. Infect Immun 1996;64:1609–1613.PubMedGoogle Scholar
  8. 8.
    Ismail N, Soong L, McBride JW, et al. Overproduction of TNF-alpha by CD8+ type 1 cells and down-regulation of IFN-gamma production by CD4+ Th1 cells contribute to toxic shock-like syndrome in an animal model of fatal monocytotropic ehrlichiosis. J Immunol 2004;172:1786–1800.PubMedGoogle Scholar
  9. 9.
    Walker DH. Rickettsioses of the spotted fever group around the world. J Dermatol 1989;16:169–177.PubMedGoogle Scholar
  10. 10.
    Murphy JR, Wisseman CL Jr, Fiset P. Mechanisms of immunity in typhus infection: some characteristics of Rickettsia mooseri infection of guinea pigs. Infect Immun 1978;21:417–424.PubMedGoogle Scholar
  11. 11.
    Shi RJ, Simpson-Haidaris PJ, Lerner NB, et al. Transcriptional regulation of endothelial cell tissue factor expression during Rickettsia rickettsii infection: involvement of the transcription factor NF-kappaB. Infect Immun 1998;66:1070–1075.PubMedGoogle Scholar
  12. 12.
    Sporn LA, Lawrence SO, Silverman DJ, Marder VJ. Eselectin-dependent neutrophil adhesion to Rickettsia rickettsii-infected endothelial cells. Blood 1993;81:2406–2412.PubMedGoogle Scholar
  13. 13.
    Sahni SK, Rydkina E, Sahni A, et al. Potential roles for regulatory oxygenases in rickettsial pathogenesis. Ann NY Acad Sci 2005;1063:207–214.CrossRefPubMedGoogle Scholar
  14. 14.
    McCook TA, Briley C, Ravin CE. Roentgenographic abnormalities in Rocky Mountain spotted fever. South Med J 1982;75:156–157.PubMedGoogle Scholar
  15. 15.
    Martinez JJ, Seveau S, Veiga E, et al. Ku70, a component of DNA-dependent protein kinase, is a mammalian receptor for Rickettsia conorii. Cell 2005;123:1013–1023.CrossRefPubMedGoogle Scholar
  16. 16.
    Uchiyama T, Kawano H, Kusuhara Y. The major outer membrane protein rOmpB of spotted fever group rickettsiae functions in the rickettsial adherence to and invasion of Vero cells. Microbes Infect 2006;8:801–809.CrossRefPubMedGoogle Scholar
  17. 17.
    Li H, Walker DH. rOmpA is a critical protein for the adhesion of Rickettsia rickettsii to host cells. Microb Pathog 1998;24:289–298.CrossRefPubMedGoogle Scholar
  18. 18.
    Martinez JJ, Cossart P. Early signaling events involved in the entry of Rickettsia conorii into mammalian cells. J Cell Sci 2004;117:5097–5106.CrossRefPubMedGoogle Scholar
  19. 19.
    Gouin E, Egile C, Dehoux P, et al. The RickA protein of Rickettsia conorii activates the Arp2/3 complex. Nature 2004;427:457–461.CrossRefPubMedGoogle Scholar
  20. 20.
    Renesto P, Dehoux P, Gouin E, et al. Identification and characterization of a phospholipase D-superfamily gene in rickettsiae. J Infect Dis 2003;188:1276–1283.CrossRefPubMedGoogle Scholar
  21. 21.
    Whitworth T, Popov VL, Yu XJ, et al. Expression of the Rickettsia prowazekii pld or tlyC gene in Salmonella enterica serovar Typhimurium mediates phagosomal escape. Infect Immun 2005;73:6668–6673.CrossRefPubMedGoogle Scholar
  22. 22.
    Eremeeva ME, Silverman DJ. Effects of the antioxidant alpha-lipoic acid on human umbilical vein endothelial cells infected with Rickettsia rickettsii. Infect Immun 1998;66:2290–2299.PubMedGoogle Scholar
  23. 23.
    Silverman DJ, Santucci LA. Potential for free radicalinduced lipid peroxidation as a cause of endothelial cell injury in Rocky Mountain spotted fever. Infect Immun 1988;56:3110–3115.PubMedGoogle Scholar
  24. 24.
    Clifton DR, Rydkina E, Huyck H, et al. Expression and secretion of chemotactic cytokines IL-8 and MCP-1 by human endothelial cells after Rickettsia rickettsii infection: regulation by nuclear transcription factor NF-kappaB. Int J Med Microbiol 2005;295:267–278.CrossRefPubMedGoogle Scholar
  25. 25.
    Sporn LA, Shi RJ, Lawrence SO, et al. Rickettsia rickettsii infection of cultured endothelial cells induces release of large von Willebrand factor multimers from Weibel-Palade bodies. Blood 1991;78:2595–2602.PubMedGoogle Scholar
  26. 26.
    Clifton DR, Rydkina E, Freeman RS, Sahni SK. NF-kappaB activation during Rickettsia rickettsii infection of endothelial cells involves the activation of catalytic IkappaB kinases IKKalpha and IKKbeta and phosphorylation-proteolysis of the inhibitor protein IkappaBalpha. Infect Immun 2005;73:155–165.CrossRefPubMedGoogle Scholar
  27. 27.
    Sporn LA, Sahni SK, Lerner NB, et al. Rickettsia rickettsii infection of cultured human endothelial cells induces NF-kappaB activation. Infect Immun 1997;65:2786–2791.PubMedGoogle Scholar
  28. 28.
    Rydkina E, Silverman DJ, Sahni SK. Activation of p38 stress-activated protein kinase during Rickettsia rickettsii infection of human endothelial cells: role in the induction of chemokine response. Cell Microbiol 2005;7:1519–1530.CrossRefPubMedGoogle Scholar
  29. 29.
    Sahni SK, Turpin LC, Brown TL, Sporn LA. Involvement of protein kinase C in Rickettsia rickettsii-induced transcriptional activation of the host endothelial cell. Infect Immun 1999;67:6418–6423.PubMedGoogle Scholar
  30. 30.
    Valbuena G, Feng HM, Walker DH. Mechanisms of immunity against rickettsiae. New perspectives and opportunities offered by unusual intracellular parasites. Microbes Infect 2002;4:625–633.CrossRefPubMedGoogle Scholar
  31. 31.
    Dumler JS, Walker DH. Rocky Mountain spotted fever—changing ecology and persisting virulence. N Engl J Med 2005;353:551–553.CrossRefPubMedGoogle Scholar
  32. 32.
    Sexton DJ, Kanj SS, Wilson K, et al. The use of a polymerase chain reaction as a diagnostic test for Rocky Mountain spotted fever. Am J Trop Med Hyg 1994;50:59–63.PubMedGoogle Scholar
  33. 33.
    Demma LJ, Traeger MS, Nicholson WL, et al. Rocky Mountain spotted fever from an unexpected tick vector in Arizona. N Engl J Med 2005;353:587–594.CrossRefPubMedGoogle Scholar
  34. 34.
    Paddock CD, Greer PW, Ferebee TL, et al. Hidden mortality attributable to Rocky Mountain spotted fever: immunohistochemical detection of fatal, serologically unconfirmed disease. J Infect Dis 1999;179:1469–1476.CrossRefPubMedGoogle Scholar
  35. 35.
    Paddock CD, Childs JE. Ehrlichia chaffeensis: a prototypical emerging pathogen. Clin Microbiol Rev 2003;16:37–64.CrossRefPubMedGoogle Scholar
  36. 36.
    Barnewall RE, Rikihisa Y, Lee EH. Ehrlichia chaffeensis inclusions are early endosomes which selectively accumulate transferrin receptor. Infect Immun 1997;65:1455–1461.PubMedGoogle Scholar
  37. 37.
    Lee EH, Rikihisa Y. Anti-Ehrlichia chaffeensis antibody complexed with E. chaffeensis induces potent proinflammatory cytokine mRNA expression in human monocytes through sustained reduction of IkappaB-alpha and activation of NF-kappaB. Infect Immun 1997;65:2890–2897.PubMedGoogle Scholar
  38. 38.
    Lin M, Rikihisa Y. Ehrlichia chaffeensis and Anaplasma phagocytophilum lack genes for lipid A biosynthesis and incorporate cholesterol for their survival. Infect Immun 2003;71:5324–5331.CrossRefPubMedGoogle Scholar
  39. 39.
    Paparone PW, Ljubich P, Rosman GA, Nazha NT. Ehrlichiosis with pancytopenia and ARDS. NJ Med 1995;92:381–385.Google Scholar
  40. 40.
    Marty AM, Dumler JS, Imes G, et al. Ehrlichiosis mimicking thrombotic thrombocytopenic purpura. Case report and pathological correlation. Hum Pathol 1995;26:920–925.CrossRefPubMedGoogle Scholar
  41. 41.
    Walker DH. Ehrlichia under our noses and no one notices. Arch Virol Suppl 2005:147–156.Google Scholar
  42. 42.
    Safdar N, Love RB, Maki DG. Severe Ehrlichia chaffeensis infection in a lung transplant recipient: a review of ehrlichiosis in the immunocompromised patient. Emerg Infect Dis 2002;8:320–323.CrossRefPubMedGoogle Scholar
  43. 43.
    Patel RG, Byrd MA. Near fatal acute respiratory distress syndrome in a patient with human ehrlichiosis. South Med J 1999;92:333–335.PubMedGoogle Scholar
  44. 44.
    Smith Sehdev AE, Sehdev PS, Jacobs R, Dumler JS. Human monocytic ehrlichiosis presenting as acute appendicitis during pregnancy. Clin Infect Dis 2002;35:e99–e102.CrossRefPubMedGoogle Scholar
  45. 45.
    Ismail N, Walker DH. Balancing protective immunity and immunopathology: a unifying model of monocytotropic ehrlichiosis. Ann NY Acad Sci 2005;1063:383–394.CrossRefPubMedGoogle Scholar
  46. 46.
    Zhang JZ, McBride JW, Yu XJ. L-selectin and E-selectin expressed on monocytes mediating Ehrlichia chaffeensis attachment onto host cells. FEMS Microbiol Lett 2003;227:303–309.CrossRefPubMedGoogle Scholar
  47. 47.
    Popov VL, Yu X, Walker DH. The 120 kDa outer membrane protein of Ehrlichia chaffeensis: preferential expression on dense-core cells and gene expression in Escherichia coli associated with attachment and entry. Microb Pathog 2000;28:71–80.CrossRefPubMedGoogle Scholar
  48. 48.
    Rikihisa Y. Ehrlichia subversion of host innate responses. Curr Opin Microbiol 2006;9:95–101.CrossRefPubMedGoogle Scholar
  49. 49.
    Zhang JZ, Sinha M, Luxon BA, Yu XJ. Survival strategy of obligately intracellular Ehrlichia chaffeensis: novel modulation of immune response and host cell cycles. Infect Immun 2004;72:498–507.CrossRefPubMedGoogle Scholar
  50. 50.
    Dierberg KL, Dumler JS. Lymph node hemophagocytosis in rickettsial diseases: a pathogenetic role for CD8 T lymphocytes in human monocytic ehrlichiosis (HME)? BMC Infect Dis 2006;6:121.CrossRefPubMedGoogle Scholar
  51. 51.
    Ismail N, Stevenson HL, Walker DH. Role of tumor necrosis factor alpha (TNF-alpha) and interleukin-10 in the pathogenesis of severe murine monocytotropic ehrlichiosis: increased resistance of TNF receptor p55-and p75-deficient mice to fatal ehrlichial infection. Infect Immun 2006;74:1846–1856.CrossRefPubMedGoogle Scholar
  52. 52.
    Stone JH, Dierberg K, Aram G, Dumler JS. Human monocytic ehrlichiosis. JAMA 2004;292:2263–2270.CrossRefPubMedGoogle Scholar
  53. 53.
    Winslow GM, Bitsaktsis C, Yager E. Susceptibility and resistance to monocytic ehrlichiosis in the mouse. Ann NY Acad Sci 2005;1063:395–402.CrossRefPubMedGoogle Scholar
  54. 54.
    Ganta RR, Cheng C, Wilkerson MJ, Chapes SK. Delayed clearance of Ehrlichia chaffeensis infection in CD4+ T-cell knockout mice. Infect Immun 2004;72:159–167.CrossRefPubMedGoogle Scholar
  55. 55.
    Ganta RR, Wilkerson MJ, Cheng C, et al. Persistent Ehrlichia chaffeensis infection occurs in the absence of functional major histocompatibility complex class II genes. Infect Immun 2002;70:380–388.CrossRefPubMedGoogle Scholar
  56. 56.
    Sotomayor EA, Popov VL, Feng HM, et al. Animal model of fatal human monocytotropic ehrlichiosis. Am J Pathol 2001;158:757–769.PubMedGoogle Scholar
  57. 57.
    Yager E, Bitsaktsis C, Nandi B, et al. Essential role for humoral immunity during Ehrlichia infection in immunocompetent mice. Infect Immun 2005;73:8009–8016.CrossRefPubMedGoogle Scholar
  58. 58.
    Stevenson HL, Jordan JM, Peerwani Z, et al. An intradermal environment promotes a protective type-1 response against lethal systemic monocytotropic ehrlichial infection. Infect Immun 2006;74:4856–4864.CrossRefPubMedGoogle Scholar
  59. 59.
    Winslow GM, Yager E, Shilo K, et al. Infection of the laboratory mouse with the intracellular pathogen Ehrlichia chaffeensis. Infect Immun 1998;66:3892–3899.PubMedGoogle Scholar
  60. 60.
    Li JS, Chu F, Reilly A, Winslow GM. Antibodies highly effective in SCID mice during infection by the intracellular bacterium Ehrlichia chaffeensis are of picomolar affinity and exhibit preferential epitope and isotype utilization. J Immunol 2002;169:1419–1425.PubMedGoogle Scholar
  61. 61.
    Winslow GM, Yager E, Li JS. Mechanisms of humoral immunity during Ehrlichia chaffeensis infection. Ann NY Acad Sci 2003;990:435–443.CrossRefPubMedGoogle Scholar
  62. 62.
    Winslow GM, Yager E, Shilo K, et al. Antibody-mediated elimination of the obligate intracellular bacterial pathogen Ehrlichia chaffeensis during active infection. Infect Immun 2000;68:2187–2195.CrossRefPubMedGoogle Scholar
  63. 63.
    Dumler JS, Dawson JE, Walker DH. Human ehrlichiosis: hematopathology and immunohistologic detection of Ehrlichia chaffeensis. Hum Pathol 1993;24:391–396.CrossRefPubMedGoogle Scholar
  64. 64.
    Dawson JE, Paddock CD, Warner CK, et al. Tissue diagnosis of Ehrlichia chaffeensis in patients with fatal ehrlichiosis by use of immunohistochemistry, in situ hybridization, and polymerase chain reaction. Am J Trop Med Hyg 2001;65:603–609.PubMedGoogle Scholar
  65. 65.
    Dunning Hotopp JC, Lin M, Madupu R, et al. Comparative genomics of emerging human ehrlichiosis agents. PLoS Genet 2006;2:e21.CrossRefGoogle Scholar
  66. 66.
    Long SW, Whitworth TJ, Walker DH, Yu XJ. Overcoming barriers to the transformation of the genus Ehrlichia. Ann NY Acad Sci 2005;1063:403–410.CrossRefPubMedGoogle Scholar
  67. 67.
    Rachek LI, Hines A, Tucker AM, et al. Transformation of Rickettsia prowazekii to erythromycin resistance encoded by the Escherichia coli ereB gene. J Bacteriol 2000;182:3289–3291.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • J. Stephen Dumler
    • 1
  1. 1.Division of Medical Microbiology, Department of PathologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations